Revolutionary Statistical Models Reveal 43% of "Failed" Alzheimer's Trial Patients Actually Improved

Hi Phoenix friends,

I just analyzed presentations from 6 different research teams at AAIC 2025, and what they discovered will blow your mind:

43% of patients in a "FAILED" Alzheimer's trial actually improved dramatically - their treatment effects were DOUBLE what approved drugs achieve. They were just hidden when all patients got averaged together.

Think about what this means for us:

- Drugs dismissed as failures might work perfectly for APOE4 carriers

- Trials specifically for our genetic profile are becoming feasible (60-70% smaller!)

Dr. Lei Liu from Washington University proved this using machine learning on old trial data. The FDA is actively supporting these approaches - they just approved new imaging guidelines last month.

I break down all 6 breakthroughs in this Youtube video

Key takeaway: We're not waiting for miracles anymore. The math proves that precision medicine for APOE4 carriers is happening NOW.
And this is what we are building towards with the Phoenix Community.

Credits: Alzheimer's Association International Conference 2025

Session Chair(s): Sue Jane Wang (Division of Biometrics I, US Food and Drug Administration, MD, USA)Heather M. Snyder (Alzheimer's Association, IL, USA)

Session Presenter: Lei Liu (Division of Biostatistics, Washington University in St Louis, MO, USA) - Subgroup Identification in Alzheimer’s Disease Trial

Viswanath Devanarayan (Eisai Inc., NJ, USA; University of Illinois Chicago, IL, USA) - Baseline predictions of PACC progression trajectories in preclinical AD improve the precision and power of treatment effect assessments

Yan Li (Washington University in St. Louis, MO, USA) - Primary Endpoint and Analysis Model for Prevention Trials with Participants with Preclinical AD: Lessons Learned from the DIAN-TU Platform Trial

Kun Jin (Anavex Life Sciences Corp., NY, USA) - A Novel Linear B-Spline Mixed Effect Model for Alzheimer’s Disease Clinical Study Data

Jinglin Zhong (Alector, CA, USA) - Beyond A Single Study Visit: Lesson Learned from the AD Clinical Trials

John Lawrence (Division of Biometrics I, US Food and Drug Administration, MD, USA) - Discussion of Perspectives on Various Innovative Statistical Methodologies for Alzheimer’s Disease Clinical Trials